GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ARQT · Mar 31, 2025

Arcutis Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001787306-25-000092General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

163.44% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.92% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-46.14% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

32.84% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

25.23% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

86.59% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-37.25% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

26.64% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

14.85% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building

Mar 31, 20240/8 normalizedLevel 3 Jun 30, 20240/9 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/9 normalizedLevel 3 Sep 30, 20250/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20268/9 normalizedLevel 3 Jun 30, 20268/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 54.54%
Current: 163.44%
Delta: 108.89%

Capex Intensity Increased

Previous: 0.07%
Current: 0.92%
Delta: 0.85%

Cash Generation Increased

Previous: -57.07%
Current: -46.14%
Delta: 10.93%

Inventory Pressure Increased

Previous: 7.39%
Current: 25.23%
Delta: 17.84%

Margin Decreased

Previous: 90.27%
Current: 86.59%
Delta: -3.68%

Profitability Increased

Previous: -65.33%
Current: -37.25%
Delta: 28.08%

R And D Intensity Decreased

Previous: 38.88%
Current: 26.64%
Delta: -12.24%

Sbc Intensity Decreased

Previous: 21.23%
Current: 14.85%
Delta: -6.38%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ARQT Fundamental State →Has State · Arcutis Biotherapeutics, Inc. →Transitioned To · ARQT Fundamental State →Transitioned To · ARQT BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ARQT CAPEX_INTENSITY_INCREASED →Transitioned To · ARQT CASH_GENERATION_INCREASED →Transitioned To · ARQT INVENTORY_PRESSURE_INCREASED →Transitioned To · ARQT MARGIN_DECREASED →Transitioned To · ARQT PROFITABILITY_INCREASED →Transitioned To · ARQT R_AND_D_INTENSITY_DECREASED →Transitioned To · ARQT SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.